20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Metastasis is responsible for most cancer-related deaths, and, among common tumor types, melanoma is one with great potential to metastasize. Here we study the contribution of epigenetic changes to the dissemination process by analyzing the changes that occur at the DNA methylation level between primary cancer cells and metastases. We found a hypomethylation event that reactivates a cryptic transcript of the Rab GTPase activating protein TBC1D16 (TBC1D16-47 kDa; referred to hereafter as TBC1D16-47KD) to be a characteristic feature of the metastatic cascade. This short isoform of TBC1D16 exacerbates melanoma growth and metastasis both in vitro and in vivo. By combining immunoprecipitation and mass spectrometry, we identified RAB5C as a new TBC1D16 target and showed that it regulates EGFR in melanoma cells. We also found that epigenetic reactivation of TBC1D16-47KD is associated with poor clinical outcome in melanoma, while conferring greater sensitivity to BRAF and MEK inhibitors.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Melanoma biology and new targeted therapy.

          Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin. The incidence of melanoma is rising steadily in western populations--the number of cases worldwide has doubled in the past 20 years. In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies. Recent discoveries in cell signalling have provided greater understanding of the biology that underlies melanoma, and these advances are being exploited to provide targeted drugs and new therapeutic approaches.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A microRNA DNA methylation signature for human cancer metastasis.

            MicroRNAs (miRNAs) are small, noncoding RNAs that can contribute to cancer development and progression by acting as oncogenes or tumor suppressor genes. Recent studies have also linked different sets of miRNAs to metastasis through either the promotion or suppression of this malignant process. Interestingly, epigenetic silencing of miRNAs with tumor suppressor features by CpG island hypermethylation is also emerging as a common hallmark of human tumors. Thus, we wondered whether there was a miRNA hypermethylation profile characteristic of human metastasis. We used a pharmacological and genomic approach to reveal this aberrant epigenetic silencing program by treating lymph node metastatic cancer cells with a DNA demethylating agent followed by hybridization to an expression microarray. Among the miRNAs that were reactivated upon drug treatment, miR-148a, miR-34b/c, and miR-9 were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues. The reintroduction of miR-148a and miR-34b/c in cancer cells with epigenetic inactivation inhibited their motility, reduced tumor growth, and inhibited metastasis formation in xenograft models, with an associated down-regulation of the miRNA oncogenic target genes, such as C-MYC, E2F3, CDK6, and TGIF2. Most important, the involvement of miR-148a, miR-34b/c, and miR-9 hypermethylation in metastasis formation was also suggested in human primary malignancies (n = 207) because it was significantly associated with the appearance of lymph node metastasis. Our findings indicate that DNA methylation-associated silencing of tumor suppressor miRNAs contributes to the development of human cancer metastasis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

              The REMARK “elaboration and explanation” guideline, by Doug Altman and colleagues, provides a detailed reference for authors on important issues to consider when designing, conducting, and analyzing tumor marker prognostic studies.
                Bookmark

                Author and article information

                Journal
                Nat. Med.
                Nature medicine
                1546-170X
                1078-8956
                Jul 2015
                : 21
                : 7
                Affiliations
                [1 ] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
                [2 ] Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, UK.
                [3 ] Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
                [4 ] Department of Pathological Anatomy, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
                [5 ] Medical Oncology Service, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.
                [6 ] Pathology Department, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.
                [7 ] Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain.
                [8 ] Dermatology Service, Hospital La Fe, Universidad de Valencia, Valencia, Spain.
                [9 ] Medical Oncology Service, Hospital General, Valencia, Spain.
                [10 ] Department of Pathology, University Hospital of Uppsala, Uppsala, Sweden.
                [11 ] Translational Cell &Tissue Pathology, Katholieke Universiteit Leuven, Leuven, Belgium.
                [12 ] University College Dublin School of Biomolecular and Biomedical Science, University College Dublin Conway Institute, University College Dublin, Belfield, Dublin, Ireland.
                [13 ] Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
                [14 ] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
                [15 ] University of Manchester, Christie National Health Service Foundation Trust, Manchester, UK.
                [16 ] 1] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain. [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. [3] Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.
                Article
                nm.3863 EMS69047
                10.1038/nm.3863
                26030178
                eec6d191-fc0d-4e88-b0f6-6ea39295a9ef
                History

                Comments

                Comment on this article